Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA H1047R |
Therapy | STX-478 |
Indication/Tumor Type | Her2-receptor positive breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA H1047R | Her2-receptor positive breast cancer | sensitive | STX-478 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, STX-478 inhibited viability in a hormone receptor-negative, ERBB2 (HER2)-positive breast cancer cell line harboring PIK3CA H1047R in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 37623743). | 37623743 |
PubMed Id | Reference Title | Details |
---|---|---|
(37623743) | STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts. | Full reference... |